RENX.L - Renalytix AI plc

LSE - LSE Delayed Price. Currency in GBp

Renalytix AI plc

Avon House
19 Stanwell Road Penarth
Cardiff CF64 2EZ
United Kingdom

IndustryDiagnostics & Research
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. James R. McCulloughCEO & DirectorN/AN/A1968
Mr. Thomas H. McLainPres & Chief Commercial OfficerN/AN/A1959
Mr. Oliver James Sterling IIIChief Financial OfficerN/AN/AN/A
Dr. Sally BowdenChief Operating OfficerN/AN/AN/A
Fergus FlemingCTO & DirectorN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Renalytix AI plc develops artificial intelligence (AI) enabled clinical decision support solutions for kidney disease. It is developing KidneyIntelX, an AI-enabled, clinical-laboratory based solution that supports physician decision making by improving identification, prediction, and risk stratification of patients with kidney disease. The company is based in Cardiff, the United Kingdom. Renalytix AI plc (AIM:RENX) operates independently of EKF Diagnostics Holdings plc as of November 2, 2018.

Corporate Governance

Renalytix AI plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.